[Research Bulletin] "Recent media reports have suggested that an agent called rituximab may be an effective therapy for MS": Rituxumab is currently being studied in a multi-center Phase II/III trial involving primary progressive MS, and a Phase II trial in secondary progressive MS, and results from these studies are not yet available.....About Rituximab: This agent, which is given as an infusion into the vein, binds to a molecule (CD20) on the surface of B cells and depletes them from the circulation.........."